Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020)

Silence Therapeutics has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $33011.3 in Q4 2020.

• Quarterly Non-Current Deferred Tax Liability rose 6.98% year-over-year to $33011.3 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $33011.3 (up 6.98% YoY) and the FY2020 annual result came in at $32103.7, up 4.76% from the prior year.
• Non-Current Deferred Tax Liability grew to $33011.3 in Q4 2020 per SLN's latest filing, from $30857.4 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $33011.3 in Q4 2020 and troughed at $16728.0 in Q4 2018.
• A 3-year average of $26865.5 and a median of $30857.4 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability jumped 84.47% in 2019, then increased 6.98% in 2020.
• Over 3 years, Non-Current Deferred Tax Liability stood at $16728.0 in 2018, then soared by 84.47% to $30857.4 in 2019, then climbed by 6.98% to $33011.3 in 2020.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $33011.3, $30857.4, and $16728.0 for Q4 2020, Q4 2019, and Q4 2018 respectively.